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OBJECTIVE— This study examines the association of A1C with cardiovascular disease
(CVD) risk factors, coronary artery disease (CAD), and metabolic syndrome in Asian Indians
with normal glucose tolerance (NGT).
RESEARCHDESIGNANDMETHODS— This cross-sectional study recruited subjects
from phase III of the Chennai Urban Rural Epidemiology Study (CURES), an epidemiological
study in a representative population of Chennai (formerly Madras) in South India, conducted
between January 2003 and June 2004. Included were 1,644 subjects with NGT, i.e., fasting
plasma glucose 100 mg/dl (5.6 mmol/l) and 2-h postload plasma glucose 140 mg/dl (7.8
mmol/l). A1C was measured using the Biorad Variant machine. Metabolic syndrome was defined
based on modified Adult Treatment Panel III guidelines.
RESULTS— The mean SD A1C value in the study cohort was 5.5 0.4%. A1C showed a
significant association with BMI (  0.017, P  0.001), systolic (  0.002, P  0.028) and
diastolic (  0.202, P 0.017) blood pressure, waist circumference (  0.007, P 0.001),
serum cholesterol ( 0.002, P 0.001), triglycerides ( 0.001, P 0.001), LDL cholesterol
(  0.002, P  0.001), fasting insulin (  0.009, P  0.001), and homeostasis model
assessment of insulin resistance (  0.047, P 0.001) after adjusting for age and sex. Regres-
sion analysis showed that A1C had a strong association with metabolic syndrome that persisted
after adjusting for age and sex (odds ratio [OR] 2.9 [95% CI 2.08–4.00]; P 0.001). A1C also
had a strong association with CAD (2.6 [1.23–5.63]; P  0.01), but the significance was lost
when adjusted for age and sex.
CONCLUSIONS— There is a strong association of A1C with prevalent CVD risk factors in
Asian-Indian subjects with NGT.
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T he DCCT (Diabetes Control andComplications Trial) and UKPDS(UK Prospective Diabetes Study)
demonstrated the importance of A1C in
the development of long-term diabetes
microvascular complications (1,2). Fur-
ther, both studies elegantly demonstrated
significant reductions in the risk of devel-
oping microvascular complications for
every percentage of reduction in A1C lev-
els (1,2). However, the association of A1C
with cardiovascular disease (CVD) is less
clear (3–8).
CVD is the principal cause of mortal-
ity globally, particularly in type 2 diabetic
subjects, as their CVD mortality risk is
equal to that of subjects without diabetes
who had a previous episode of myocardial
infarction (9). Recent prospective studies
have shown that A1C is associated with
CVD and mortality (10). This association
has also recently been extended to nondi-
abetic subjects, as the relationship of CVD
with glycemia is believed to be a contin-
uum without a threshold effect (5–8).
However, there is uncertainty as to the
nature of the relationship, as some studies
report no statistically significant associa-
tion (3) between A1C and CVD in nondi-
abetic males while others do (4–8).
Asian Indians are known to have very
high rates of premature coronary artery
disease (CAD) and diabetes (11). This is
attributed to the so-called Asian-Indian
phenotype (12), characterized by rela-
tively lower prevalence rates of obesity
but larger waist measurements indicating
abdominal obesity and increased insulin
resistance. In keeping with studies in the
West (13), we have shown that in Asian
Indians also, the risk for CVD starts at the
stage of impaired glucose tolerance (IGT)
(14). However, to our knowledge, there
are no data on the association of A1C with
CVD risk in Asian Indians with normal
glucose tolerance (NGT). It would be
worthwhile to look at the association of
A1C with CVD risk factors in Asian Indi-
ans, as a recent analysis of global and re-
gional mortality indicated that South
Asians had the highest mortality rates due
to ischemic heart disease compared with
other countries and also had higher mean
plasma glucose levels (15). This study ex-
amines the association of A1C with CVD
risk factors, CAD, and metabolic syn-
drome in Asian Indians with NGT.
RESEARCH DESIGN AND
METHODS— The Chennai Urban
Rural Epidemiology Study (CURES) is a
large, cross-sectional study conducted in
a representative population of Chennai
(formerly Madras), the largest city in
Southern India, with a population of ap-
proximately 5 million people. The meth-
odology of CURES has been reported
elsewhere (16). Briefly, the sampling for
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CURES was based on the model of sys-
tematic random sampling, wherein, of the
155 wards in Chennai, 46 were selected
to provide a total sample size of 26,001
individuals 20 years of age. Phase I of
CURES was conducted in the field and
involved a door-to-door survey in the se-
lected wards. In Phase II, all the known
diabetic subjects and age- and sex-
matched nondiabetic subjects were
brought to our center for detailed anthro-
pometric measurements and biochemical
tests.
This study recruited subjects from
Phase III, in which every 10th subject re-
cruited in Phase I were brought to the
center for detailed studies, inclusive of
oral glucose tolerance in those without
self-reported diabetes. Phase III had a
90% response rate (2,350 of 2,600). Sub-
jects with diabetes, (IGT), and impaired
fasting glucose (17,18) were excluded
from the present study, which deals only
with subjects who had NGT (n 1,644),
defined as fasting plasma glucose 100
mg/dl (5.6 mmol/l) and 2-h postload
plasma glucose 140 mg/dl (7.8 mmol/
l). Of the 1,644 NGT subjects identified in
Phase III, A1C tests were conducted in
1,632 (99.3%). Subjects with A1C
7.0% were excluded (n  5).
Anthropometric measurements
Weight, height, and waist measurements
were obtained using standardized tech-
niques as detailed elsewhere (16). Height
was measured with a tape to the nearest
centimeter. Weight was measured with a
traditional spring balance that was kept
on a firm horizontal surface. Waist size
was measured using a nonstretchable fi-
ber measure tape. BMI was calculated as
the weight in kilograms divided by the
square of height in meters. Blood pres-
sure was recorded in the sitting position
using the right arm to the nearest 2
mmHg with a mercury sphygmomanom-
eter (Diamond Deluxe; Pune, India). Two
readings were taken 5 min apart, and the
mean of the two was taken as the blood
pressure.
Biochemical parameters
Fasting plasma glucose (glucose oxidase-
peroxidase method), serum cholesterol
(cholesterol oxidase-peroxidase-4 –
aminophenazone method) serum triglyc-
erides (glycerol phosphate oxidase-
p e r o x i d a s e - 4 – a m i n o p h e n a z o n e
method), and HDL cholesterol (direct
method with polyethylene glycol–
pretreated enzymes) were measured us-
ing the Hitachi-912 Autoanalyser
(Hitachi, Mannheim, Germany). The in-
tra- and interassay coefficient of variation
(CV) for the biochemical assays ranged
between 3.1 and 7.6%. LDL cholesterol
was calculated using the Friedewald for-
mula (19) in subjects with triglycerides
400 mg/dl (n  1,618). Serum insulin
concentration was estimated using Dako
kits (Dako, Glostrup, Denmark); 1,515
individuals (92.8%) provided a sample
for insulin assay. Insulin resistance was
estimated using the homeostasis assess-
ment model of insulin resistance (HOMA-
IR): fasting insulin (U/ml)  fasting
glucose (mmol/l)/22.5 (20).
Analysis of A1C
A1C was measured using a Variant ma-
chine (Biorad, Hercules, CA). Our center
participates in the Unity program of Bio-
rad A1C standardization. The CV for A1C
assay was 3.5%. The CV for inhouse qual-
ity control was 2.5%. In the external
quality assessment scheme, bias for A1C
analysis was 1.75% and imprecision
2.75%, indicating good reproducibility.
Definitions and diagnostic criteria
Metabolic abnormalities. Hypercholes-
terolemia (serum cholesterol 5.2
mmol/l [200 mg/dl] or subjects who
self-reported hypercholesterolemia and
were on statins), hypertriglyceridemia
(serum triglycerides1.7 mmol/l [150
mg/dl] or subjects who self-reported hy-
pertriglyceridemia and were on drugs for
hypertriglyceridemia), and low HDL cho-
lesterol (male subjects: HDL cholesterol
1.04 mmol/l [ 40 mg/dl] and female
subjects: HDL cholesterol 1.3 mmol/l
[ 50 mg/dl]) were diagnosed based on
Adult Treatment Panel (ATP) III guide-
lines (21). Metabolic syndrome was diag-
nosed based on modified ATP III
guidelines (21) if any three of the follow-
ing abnormalities were present: abdomi-
na l obes i ty (defined as wa i s t
circumference 90 cm for male subjects
and 80 cm for female subjects, accord-
ing to modified Asia Pacific World Health
Organization guidelines) (22), high blood
pressure (systolic blood pressure [sBP]
130 mmHg. diastolic blood pressure
[dBP] 85 mmHg, or subjects who self-
reported hypertension and were on anti-
hypertensives), hypertriglyceridemia, or
low HDL cholesterol. Obesity was defined
as BMI25 kg/m2 according to the mod-
ified Asia Pacific World Health Organiza-
tion guidelines (22).
CAD. CAD was diagnosed based on a
past history of documented myocardial
infarction and/or medical therapy (ni-
trates) or revascularization for CAD, elec-
trocardiographic changes suggestive of
Q-wave changes (Minnesota codes 1–1-1
to 1–1-7), and/or ST segment depression
(Minnesota codes 4–1 to 4–2).
Statistical analysis
Data management was done via Microsoft
Access, and statistical analyses were done
using the SPSS statistical package (Ver-
sion 10.0; Chicago, IL). Subjects with
A1C4.0% were excluded, as this could
be due to presence of a variant A1C (n 
5). One-way ANOVA (Tukey’s honestly
significant difference comparison) were
used as appropriate to compare means
among different groups. 2 test or Fisher’s
exact test was used to compare propor-
tions among groups. Study subjects were
categorized into quartiles of A1C; un-
equal numbers were found in the quar-
tiles because of decimals. Pearson’s
correlation analysis was carried out to de-
termine the correlation of A1C with car-
diovascular risk factors. Linear regression
analysis was done using A1C as the de-
pendent variable and CVD risk factors as
independent variables. In multiple linear
regression analysis (forward method),
HOMA-IR (correlation with fasting insu-
lin CV 0.989), cholesterol (correlation
with LDL cholesterol r  0.924), and
CMI (correlation with waist circumfer-
ence r  0.823) were not included to
avoid intercorrelation between indepen-
dent variables. Logistic regression analy-
sis was done using CAD and metabolic
syndrome as dependent variables and
A1C as an independent variable. Receiv-
er-operator characteristic (ROC) curves
were constructed to identify the cut point
of A1C with maximum accuracy for de-
termining metabolic syndrome and CAD.
Sensitivity, specificity, and accuracy for
predicting metabolic syndrome were cal-
culated for different cut points of A1C.
RESULTS— The study groups in-
cluded 1,620 subjects with NGT (734
men and 886 women). Men were older
than women (38 13 vs. 36 11 years,
respectively, P 0.007), had lower BMIs
(22.3  4.0 vs. 22.8  4.1 kg/m2, P 
0.026), larger waist circumferences (83
12 vs. 80  11 cm, P  0.001), and
higher sBP (117  16 vs. 114  16
mmHg, P  0.001), dBP (74  11 vs.
72  11 mmHg, P  0.001), and serum
triglycerides (1.35 0.82 vs. 1.15 0.62
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mmol/l, P  0.001) but lower levels of
2-h postload plasma glucose (5.38 1.15
vs. 5.66  1.0 mmol/l, P  0.001) and
HDL cholesterol (1.05 0.25 vs. 1.19
0.25 mmol/l, P 0.001). Mean A1C was
5.5  0.4%, range 4.0–6.8%.
The clinical and biochemical charac-
teristics of the NGT group stratified ac-
cording to quartiles of A1C are shown in
Table 1. Age, BMI, waist circumference,
sBP and dBP, serum cholesterol, triglyc-
erides, LDL cholesterol, fasting insulin,
and HOMA-IR increased significantly
with increasing quartiles of A1C values (P
for trend 0.001). Prevalence of meta-
bolic abnormalities and the metabolic
syndrome increase corresponded with in-
creases in quartiles of A1C (P for trend
0.001), with the exception of low HDL
cholesterol levels (P for trend  0.262).
Though the prevalence of CAD increased
in the 3rd and 4th quartile compared with
the 1st quartile, the difference did not
reach statistical significance, probably be-
cause of small numbers (n  34). HDL
cholesterol failed to show any trend with
increasing quartiles of A1C levels, even
when categorized sex wise (male subjects:
1st quartile 1.06  0.27 mmol/l, 2nd
quartile 1.04 0.24 mmol/l, 3rd quartile
1.05  0.25 mmol/l, and 4th quartile
1.04  0.23 mmol/l; female subjects: 1st
quartile 1.19 0.24 mmol/l, 2nd quartile
1.18 0.28 mmol/l, 3rd quartile 1.20
0.26 mmol/l, and 4th quartile 1.17 
0.22 mmol/l).
There was a linear increase in the
mean values of A1C with an increase in
number of components of metabolic syn-
drome (one metabolic abnormality: 5.5
0.4, two metabolic abnormalities: 5.6 
0.5, three or more metabolic abnormali-
ties: 5.7  0.5) compared with subjects
with no metabolic abnormalities (5.4 
0.4), P for trend 0.001).
Table 2 presents the results of the
Pearson’s correlation analysis of A1C with
cardiovascular risk factors. A1C had a sig-
nificant correlation with age, BMI, waist
circumference, sBP and dBP, serum cho-
lesterol, triglycerides, LDL cholesterol,
fasting insulin levels, and HOMA-IR (P
0.001).
Table 3 presents the results of linear
regression analysis using A1C as a depen-
dent variable and CVD risk factors as in-
dependent variables. A1C showed a
s ignificant assoc ia t ion with BMI
(  0.017, P 0.001), sBP (P 0.028),
dBP (P  0.017), waist circumference
(P  0.001), serum cholesterol (P 
0.001), triglycerides (P  0.001), LDL
cholesterol (P  0.001), fasting insulin
(P  0.001), and HOMA-IR (P  0.001)
even after adjusting for age and sex, with
the exception of HDL cholesterol, which
showed an association with A1C only af-
ter adding age and sex into the model
( 0.003, P 0.006). However, this
Table 1—Clinical and biochemical characteristics of the study population according to quartiles of A1C
Parameters
Quartiles of A1C
P for trend1st 2nd 3rd 4th
n 316 426 426 452 —
A1C (%) 5.1 5.1–5.4 5.5–5.7 	5.7 —
Age (years) 33  11 34  10 38  11* 42  13†  0.001
Sex (male) 147 (46.5) 185 (43.4) 189 (44.4) 213 (47.1) 0.694
BMI (kg/m2) 21.59  3.96 22.35  4.06 22.58  4.18‡ 23.52  3.91§  0.001
Waist circumference (cm) 78  12 80  11 81  12¶ 85  11  0.001
sBP (mmHg) 112  15 114  14 116  17‡ 119  17**  0.001
dBP (mmHg) 70  11 72  11 73  11‡ 74  10*  0.001
Fasting plasma glucose (mmol/l) 4.51  0.40 4.57  0.36 4.66  0.40§ 4.73  0.38††  0.001
2-h plasma glucose (mmol/l) 5.43  1.04 5.45  1.08 5.43  1.09 5.79  1.06  0.001
Total cholesterol (mmol/l) 4.17  0.97 4.38  0.80‡ 4.56  0.91* 4.81  1.01  0.001
Serum triglycerides (mmol/l) 1.04  0.55 1.19  0.64‡ 1.26  0.68¶ 1.42  0.89**  0.001
HDL cholesterol (mmol/l) 1.13  0.26 1.12  0.27 1.14  0.27 1.11  0.23 0.396
LDL cholesterol (mmol/l) 2.56  0.86 2.72  0.68‡‡ 2.84  0.78¶ 3.05  0.86**  0.001
Fasting insulin (U/ml) 7.3  5.2 7.6  5.0 7.8  5.1 9.0  6.4†  0.001
HOMA-IR 1.47  1.07 1.55  1.07 1.63  1.09 1.89  1.34**  0.001
Hypertension 51 (16.1) 90 (21.1) 99 (23.2) 147 (32.5)  0.001
Obesity 89 (28.2) 148 (34.7) 180 (42.3) 245 (54.2)  0.001
High triglycerides 92 (29.2) 182 (42.8) 201 (47.2) 232 (51.4)  0.001
Low HDL cholesterol 183 (58.1) 268 (63.1) 270 (63.5) 293 (65.0) 0.262
Metabolic syndrome 10 (3.2%) 26 (6.1%) 35 (8.2%) 45 (10.0%)  0.001
CAD 5 (1.6%) 6 (1.5%) 10 (2.5%) 13 (3.1) 0.115
Data are means SD or n (%) unless otherwise indicated. *P 0.001 compared with 1st quartile and P 0.05 compared with 2nd quartile; †P 0.001 compared
with first quartile and P 0.01 compared with 2nd and 3rd quartiles; ‡P 0.01 compared with 1st quartile; §P 0.001 compared with 1st and 2nd quartiles; ¶P
0.001 compared with 1st quartile; P 0.001 compared with 1st, 2nd, and 3rd quartiles; **P 0.001 compared with 1st and 2nd quartile and P 0.01 compared
with 3rd quartile; ††P  0.001 compared with 1st and 2nd quartile and P  0.05 compared with 3rd quartile; and ‡‡P  0.05 compared with 1st quartile.
Table 2—Pearson correlation coefficient of
A1C with cardiovascular risk variables
Correlation r P
Age 0.292  0.001
BMI 0.159  0.001
Waist circumference 0.216  0.001
sBP 0.157  0.001
dBP 0.135  0.001
Total cholesterol 0.233  0.001
Serum triglycerides 0.180  0.001
HDL cholesterol 0.022 0.377
LDL cholesterol 0.205  0.001
Fasting insulin 0.117  0.001
HOMA-IR 0.138  0.001
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association lost its significance when trig-
lycerides were added into the model (
0.002, P 0.160). Similar results were
obtained even when categorized based on
sex (men: 0.001, P 0.574; wom-
en:   0.002, P  0.199).
Multiple linear regression analysis re-
vealed that age (P 0.001), waist circum-
ference (P  0.001), triglycerides (P 
0.003), LDL cholesterol (P 0.001), and
fasting insulin (P  0.026) had a signifi-
cant association with A1C. The model
that used only age as the independent
variable had r2 8.6%, which increased to
13.8% when waist circumference, LDL
cholesterol, triglycerides, and fasting in-
sulin were incorporated into the model.
Logistic regression using CAD as a de-
pendant variable showed that A1C had a
strong association with CAD (odds ratio
[OR] 2.6 [95% CI 1.23–5.63], P 0.01).
However, this association lost its signifi-
cance when adjusted for age (1.5 [0.666–
3.20], P  0.34), probably because of
small numbers of subjects with CAD (n
34). Regression analysis using metabolic
syndrome as a dependant variable
showed that A1C had a strong association
with metabolic syndrome (3.5 [2.53–
4.75], P  0.001), and this association
persisted even after adjusting for age (2.9
[2.08–4.01], P  0.001) and sex (2.9
[2.08–4.00], P   0.001).
ROC analysis revealed that an A1C
cut point of 5.6% had maximum accu-
racy in determining metabolic syndrome
(area under the curve 0.602, P  0.001;
accuracy 60%, sensitivity 57.5%, and
specificity 60.9%). A1C values of 5.0 and
6.0% were also analyzed to determine
their efficiency; a value of 6.0% had a sen-
sitivity of 25.8% and specificity of 87.8%,
while a value of 5.0% had a sensitivity of
96.3% and specificity of 9.8%.
With regard to CAD, ROC curves had
an area under the curve of 0.605 (P 
0.036), and A1C 5.6% had maximum ac-
curacy (56%), optimum sensitivity
(67.6%), and optimum specificity
(55.7%). A1C 6.0% had a sensitivity of
26.5% and specificity of 86.1%, while a
value of 5.0% had a sensitivity of 97.0%
and a specificity of 9.2%.
CONCLUSIONS— The main find-
ings of the study are that in Asian Indians
with NGT, A1C showed an association
with most CVD risk factors, the metabolic
syndrome, and CAD; the latter, however,
was not significant when age was intro-
duced into the model.
A1C could be considered a good
marker for glycated proteins, which play a
contributory role in atherosclerosis
(23,24) not only in diabetic but also in
nondiabetic subjects (25). This is sup-
ported by the findings that even nondia-
betic subjects with CAD have increased
levels of A1C (26).
We observed a trend in prevalence of
CAD with an increase in quartiles of A1C;
however, the difference in prevalence be-
tween quartiles did not reach statistical
significance, probably because of small
number of subjects with CAD (n  34).
While regression analysis revealed that
A1C was significantly associated with
CAD, this disappeared upon addition of
age into the model.
Prospective studies have revealed
A1C to be a predictor of total and all-
cause mortality (5,6). Indeed, the Rancho
Bernardo Study (3) concluded that A1C is
a better predictor of CVD mortality than
fasting and postload plasma glucose lev-
els. A meta-analysis of several studies con-
cluded that there is a linear relationship
between glucose levels and CVD (7). In
our population, we reported that the
prevalence of CAD is nearly 1.5 times
higher among subjects with IGT com-
pared with NGT (14). Further, preclinical
atherosclerotic markers like carotid in-
tima media thickness also showed a linear
increase with increasing severity of glu-
cose intolerance (27), indicating that the
atherosclerotic process starts to get accel-
erated even before clinical diabetes sets
in.
Insulin resistance is considered to be
the link between glucose intolerance and
CAD (28), and earlier population-based
studies demonstrated that plasma insulin
levels had a strong association with CAD
(29). In the present analysis, we observed
a strong association between A1C, fasting
insulin, and insulin resistance, indepen-
dent of age and sex. One could speculate
that this association could be through
low-grade inflammation, which is
strongly associated with insulin resistance
(30).
Studies in different ethnic groups
have assessed the relation between meta-
bolic abnormalities in terms of CVD risk
factors and A1C. Similar to these popula-
tion studies (31–33), we also found that
prevalence of all CVD risk factors in-
creased with increasing quartiles of A1C,
and the difference reached statistical sig-
nificance in the 3rd and 4th quartiles.
Similar findings were reported in African
Americans (33). However, unlike the
Chinese study in which age and sex al-
tered some of these associations (31), in
the present analysis adjustments for age
and sex did not alter the association of
A1C with CVD risk factors.
HDL cholesterol showed an associa-
tion with A1C when age and sex were in-
corporated into the model. However, this
association disappeared when triglycer-
ides were introduced into the model.
Table 3—Association of A1C with metabolic
abnormalities in nondiabetic subjects; depen-
dent variable: A1C
Independent variables  P
Waist circumference
Unadjusted 0.008 0.001
Adjusted for age
and sex
0.007 0.001
sBP
Unadjusted 0.004 0.001
Adjusted for age
and sex
0.002 0.028
dBP
Unadjusted 0.005 0.001
Adjusted for age
and sex
0.002 0.017
Total cholesterol
Unadjusted 0.003 0.001
Adjusted for age
and sex
0.002 0.001
Serum triglycerides
Unadjusted 0.001 0.001
Adjusted for age
and sex
0.001 0.001
HDL cholesterol
Unadjusted 0.001 0.377
Adjusted for age
and sex
0.003 0.006
LDL cholesterol
Unadjusted 0.003 0.001
Adjusted for age
and sex
0.002 0.001
Fasting insulin
Unadjusted 0.009 0.001
Adjusted for age
and sex
0.009 0.001
HOMA-IR
Unadjusted 0.052 0.001
Adjusted for age
and sex
0.047 0.001
Multiple linear
conclusions
regression analysis
Age 0.008 0.001
Waist
circumference
0.004 0.001
Serum triglycerides 0.001 0.003
LDL cholesterol 0.002 0.001
Fasting insulin 0.004 0.026
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These results are in accordance with those
reported in an earlier study by Bakker et
al. (34), which suggested that within the
metabolic syndrome, disturbances of
lipid and glucose coexit (34).
Multiple regression analysis using
various CVD risk factors revealed age,
waist circumference, triglycerides, LDL
cholesterol, and fasting insulin to be as-
sociated with A1C. With age, glycation
of proteins increases; this supports the
association of age with A1C observed in
this study. The strong association of
waist circumference, fasting insulin,
and triglycerides with A1C and the fact
that the prevalence of multiple sclerosis
increases with increase in A1C quartiles
suggest that A1C could be included as a
diagnostic criteria for metabolic syn-
drome instead of fasting plasma glu-
cose, particularly in situations when a
fasting sample is difficult to obtain.
The NCEP (National Cholesterol Ed-
ucation Program) ATP III guidelines rec-
ognized metabolic syndrome as a risk
factor for CAD, and this is confirmed by
several studies (21). In this study, A1C
levels increased with the number of com-
ponents of the metabolic syndrome, and
NGT subjects with three or more meta-
bolic abnormalities had the highest A1C
(5.7%). Moreover, the prevalence of met-
abolic syndrome per se increases with
quartiles of A1C. A study of African Amer-
icans suggested A1C to be a surrogate
marker for metabolic syndrome (33). In
our study, an A1C cut point 5.6% was
found to have the highest accuracy of pre-
dicting both metabolic syndrome and
CAD.
The present study supports the EPIC
(European Investigation of Cancer and
Nutrition)-Norfolk study, which reported
an association of A1C with CVD risk even
in the nondiabetic range. In that study,
0.1–0.2% reduction in A1C was shown to
reduce risk of total mortality by 5.1% (4).
Hence, estimation of A1C appears to be a
useful measure even among the nondia-
betic population in assessing an individ-
ual’s cardiovascular risk. The advantages
of this test are that it can be measured at
any time of the day with a very small
blood sample (5 l). The disadvantages
are that A1C cannot be measured in the
presence of hemoglobin variants by sev-
eral methods, costs, and the difficulty in
standardization (35).
One of the major limitations of this
study is that, as a cross-sectional study, it
cannot provide evidence for a cause-and-
effect relationship between the associa-
tion of A1C with CAD and its risk factors.
The strengths of the study, however, are
that it is population based and performed
in a population at high risk of diabetes
and premature CAD. In summary, this
study reports that among Asian Indians
who are known to have high risk of pre-
mature CAD and diabetes, a linear rela-
tionship exists between A1C, CAD, and
metabolic syndrome even among nondi-
abetic subjects.
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